Explore key fibrosis signaling pathways and their connected models and drugs.
In-depth articles on molecular mechanisms, roles in fibrosis, and drug discovery strategies for each signaling pathway.
NF-κB drives inflammation, but systemic blockade cripples host defense. Dual role in MASH, UUO, IPF models and selective IKK strategies reviewed.
Read →YAP/TAZ mechanosensors drive a stiffness-fibrosis feedback loop. Learn the Hippo pathway biology and how PCLS models target it.
Read →HIF-1α/2α master hypoxic transcription in CKD, MASH, and IPF fibrogenesis. Covers VHL-PHD regulation, organ evidence, and HIF-PHI drugs (Roxadustat).
Read →Four kinases (PERK/PKR/GCN2/HRI) converge on eIF2α-ATF4. ISR role in IPF, MASH, and neurodegeneration, plus the ISRIB-led drug development landscape.
Read →TGF-β, the fibrosis master switch, is hard to drug (immunosuppression/cancer). Non-canonical Smad and integrin inhibitors enable selective blockade.
Read →The fetal developmental program, reactivated in adults, can trigger fibrosis. We explore TGF-β crosstalk and Wnt pathway potential as a drug target.
Read →